Comparison between CARRA-JPsA onset before or at age 4 years (early onset*) and after 4 years (late onset**).
| Variable | Total CARRA-JPsA, 361 Patients | Early Onset, 82 Patients | Late Onset, 260 Patients | p*** |
|---|---|---|---|---|
| Demographic data | ||||
| Age at first rheumatology visit, yrs, mean ± SD | 9.37 ± 4.54 | 3.12 ± 2.08 | 11.25 ± 3.19 | |
| Time between symptom onset and first rheumatology visit, mean ± SD | 1.04 ± 1.46 | 1.24 ± 1.80 | 0.97 ± 1.34 | NS |
| Sex, male, n (%) | 137 (38) | 18 (22.0) | 110 (42.3) | 0.001 |
| Family history of psoriasis, n (%) | 113 (31.3) | 26 (31.9) | 83 (31.9) | NS |
| Clinical characteristics, n/total (%) | ||||
| Oligoarthritis | 160/358 (44.7) | 37/82 (45.1) | 115/257 (44.7) | NS |
| Polyarthritis | 198/358 (55.3) | 45/82 (54.9) | 142/257 (55.3) | NS |
| Nail pitting | 128/341 (37.5) | 23/77 (29.9) | 93/245 (38.0) | NS |
| Dactylitis | 102/344 (29.7) | 32/78 (41.0) | 65/247 (26.3) | 0.013 |
| Psoriasis | 233/349 (66.8) | 45/78 (57.7) | 179/253 (70.8) | 0.031 |
| Enthesitis | 112/342 (32.7) | 13/77 (16.9) | 91/247 (36.8) | 0.001 |
| Sacroiliitis | 57/342 (16.7) | 6/77 (7.8) | 47/247 (19.0) | 0.02 |
| Uveitis | 39/348 (11.2) | 15/80 (18.8) | 22/249 (8.8) | 0.015 |
| Questionnaires, mean ± SD | ||||
| HRQOL score | 2.17 ± 0.84 | 2.02 ± 0.89 | 2.21 ± 0.84 | NS |
| Parent/subject overall well-being score | 2.33 ± 2.20 | 1.83 ± 1.80 | 2.54 ± 2.31 | 0.03 |
| Parent/subject pain scale score | 2.58 ± 2.64 | 2.12 ± 2.53 | 2.75 ± 2.69 | 0.05 |
| PGA | 1.50 ± 1.71 | 1.41 ± 1.78 | 1.53 ± 1.72 | NS |
| Radiographic characteristics | ||||
| Imaging evidence of joint damage, n/total (%) | 74/301 (24.6) | 17/67 (25.4) | 50/216 (23.1) | NS |
| Laboratory data, n/total (%) | ||||
| ACPA | 7/136 (1.9) | 0/35 (0) | 7/94 (7.4) | NS |
| RF | 17/361 (4.7) | 3/82 (3.7) | 13/260 (5.0) | NS |
| ANA | 135/292 (46.2) | 42/68 (61.8) | 87/210 (41.4) | 0.003 |
| HLA-B27 | 26/246 (10.6) | 5/49 (10.2) | 18/182 (9.9) | NS |
| Medications, n/total (%) | ||||
| DMARD ever | 294/361 (81.4) | 71/82 (86.6) | 206/258 (79.8) | NS |
| bDMARD ever | 191/361 (52.9) | 49/82 (59.8) | 127/258 (49.2) | NS |
| GC | 188/361 (52.1) | 53/82 (64.6) | 122/260 (46.9) | 0.005 |
| Intraarticular GC | 118/361 (32.7) | 38/82 (46.3) | 70/260 (26.9) | 0.001 |
| Daily NSAID | 160/361 (44.3) | 25/78 (32.1) | 131/256 (51.2) | 0.003 |
| MTX | 181/361 (50.14) | 39/82 (47.6) | 142/260 (54.6) | NS |
↵* Early onset ≤ 4 years from the total of 342 patients with known age of disease onset.
↵** Late onset > 4 years from the total of 342 patients with known age of disease onset.
↵*** Specific values for p ≤ 0.05 are reported. After adjustment for multiple comparisons, the significance cutoff is p ≤ 0.006. CARRA: Childhood Arthritis and Rheumatology Research Alliance; JPsA: juvenile psoriatic arthritis; HRQOL: health-related quality of life; PGA: physician’s global assessment; ACPA: anticyclic citrullinated peptide antibodies; RF: rheumatoid factor; ANA: antinuclear antibody test; DMARD: disease-modifying antirheumatic drug; GC: glucocorticosteroids; NSAID: nonsteroidal antiinflammatory drugs; MTX: methotrexate; NS: nonsignificant.